Braz J Otorhinolaryngol:鼻光疗-过敏性鼻炎的替代疗法

2021-03-07 AlexYang MedSci原创

过敏性鼻炎是一种由免疫球蛋白E介导的鼻黏膜慢性炎症,每6个人中就有1人受到影响。治疗的目的是以最小的副作用达到症状控制,这也是对新的替代疗法的要求,包括光疗,具有免疫抑制和免疫调节作用。

过敏性鼻炎是一种由免疫球蛋白E介导的鼻黏膜慢性炎症,每6个人中就有1人受到影响。治疗的目的是以最小的副作用达到症状控制,这也是对新的替代疗法的要求,包括光疗,具有免疫抑制和免疫调节作用。

最近,有研究人员通过元分析确定光疗在治疗过敏性鼻炎中的有效性

研究人员搜索了Web of Science, Scielo, PubMed, SCOPUS, PEDro和LILACS数据库,使用了 "鼻内照射","光疗 "和 "过敏性鼻炎"术语。并采用R软件Metafor包进行元分析,分别计算各症状的效应大小。结果表明,光疗后所有症状均明显减轻:鼻出血(ES=-1.35;p<0.0001;I2=91.84%)、喷嚏(ES=-1.24;p<0.0001;I2=91.43%)、鼻腔瘙痒(ES=-1.10;p<0.0001;I2=91.43%)和鼻塞(ES=-1.11;p<0.0001;I2=91.88%)。另外,对常年性过敏性鼻炎的效果比季节型更为显著。

最后,研究人员指出,考虑到研究的效果大小和统计学意义,鼻光疗是降低AR引起的鼻部症状评分的有效治疗方法

原始出处:

Tatyana Machado Ramos Costa , Fernanda Melo Carneiro , Karen Amanda Soares de Oliveira et al. Rhinophototherapy, an alternative treatment of allergic rhinitis: Systematic review and meta-analysis. Braz J Otorhinolaryngol. Feb 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun May 16 11:11:57 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648378, encodeId=9ec316483e87e, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Sat Jul 24 17:11:57 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047389, encodeId=f5ff204e389b0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 26 00:11:57 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747905, encodeId=be4b1e47905d1, content=<a href='/topic/show?id=77d62883411' target=_blank style='color:#2F92EE;'>#光疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28834, encryptionId=77d62883411, topicName=光疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1d35982112, createdName=俅侠, createdTime=Tue Jun 08 23:11:57 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946612, encodeId=594c94661203, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Mar 08 23:23:55 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun May 16 11:11:57 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648378, encodeId=9ec316483e87e, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Sat Jul 24 17:11:57 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047389, encodeId=f5ff204e389b0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 26 00:11:57 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747905, encodeId=be4b1e47905d1, content=<a href='/topic/show?id=77d62883411' target=_blank style='color:#2F92EE;'>#光疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28834, encryptionId=77d62883411, topicName=光疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1d35982112, createdName=俅侠, createdTime=Tue Jun 08 23:11:57 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946612, encodeId=594c94661203, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Mar 08 23:23:55 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun May 16 11:11:57 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648378, encodeId=9ec316483e87e, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Sat Jul 24 17:11:57 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047389, encodeId=f5ff204e389b0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 26 00:11:57 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747905, encodeId=be4b1e47905d1, content=<a href='/topic/show?id=77d62883411' target=_blank style='color:#2F92EE;'>#光疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28834, encryptionId=77d62883411, topicName=光疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1d35982112, createdName=俅侠, createdTime=Tue Jun 08 23:11:57 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946612, encodeId=594c94661203, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Mar 08 23:23:55 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun May 16 11:11:57 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648378, encodeId=9ec316483e87e, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Sat Jul 24 17:11:57 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047389, encodeId=f5ff204e389b0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 26 00:11:57 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747905, encodeId=be4b1e47905d1, content=<a href='/topic/show?id=77d62883411' target=_blank style='color:#2F92EE;'>#光疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28834, encryptionId=77d62883411, topicName=光疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1d35982112, createdName=俅侠, createdTime=Tue Jun 08 23:11:57 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946612, encodeId=594c94661203, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Mar 08 23:23:55 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-06-08 俅侠
  5. [GetPortalCommentsPageByObjectIdResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun May 16 11:11:57 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648378, encodeId=9ec316483e87e, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Sat Jul 24 17:11:57 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047389, encodeId=f5ff204e389b0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 26 00:11:57 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747905, encodeId=be4b1e47905d1, content=<a href='/topic/show?id=77d62883411' target=_blank style='color:#2F92EE;'>#光疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28834, encryptionId=77d62883411, topicName=光疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1d35982112, createdName=俅侠, createdTime=Tue Jun 08 23:11:57 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946612, encodeId=594c94661203, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Mar 08 23:23:55 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 ms3000000449926787

    学习了

    0

相关资讯

Am J Rhinol Allergy:过敏性鼻炎患者外周血嗜碱性粒细胞中Toll-Like受体7的表达上调

之前有报道称,Toll样受体7(TLR7)激动剂可以通过促进Th1细胞因子的释放和抑制Th2细胞的功能来改善过敏性鼻炎(AR)的症状。然而,对TLR7在AR嗜碱性细胞中的表达知之甚少。

J Asthma Allergy:奥马珠单抗治疗季节性过敏性鼻炎患者的效果和响应预测因素

奥马珠单抗在治疗季节性过敏性鼻炎(SAR)方面的有效性和安全性已被多个国家的随机临床试验证实。然而,目前缺乏中国SAR患者接受奥马珠单抗治疗的临床报道。最近,研究人员在真实世界设计的研究中,调查了奥马

Brain Res:过敏性鼻炎损害工作记忆与海马-前额叶耦合下降有关

过敏性鼻炎(AR)是一种慢性炎症性疾病,常与学习和记忆的缺陷有关。

Int Arch Allergy Immunol:TGF-β信号通路基因的MicroRNA靶点的多态性与过敏性鼻炎的易感性研究

位于3'-UTR区的microRNA靶位点内的多态性可能会引起micro-RNA结合的变化,从而调节基因的表达,并与潜在的疾病相关。

World Allergy Organ J:环境暴露对过敏原致敏和儿童过敏性疾病发展的影响

环境因素的变化可能是导致儿童过敏性疾病发病率上升的原因。然而,环境暴露是否会诱发过敏原致敏,以及哪种过敏原致敏与过敏性疾病的发生有关目前尚不清楚。最近,有研究人员调查了环境暴露、过敏原致敏与过敏性疾病

Eur Arch Otorhinolaryngol:常被误诊为过敏性鼻炎的无症状过敏原致敏伴鼻中隔偏曲的临床特征

过敏性鼻炎(AR)通常是通过症状且伴有过敏原敏感性测试阳性结果来确定。然而,皮刺试验(SPT)阳性并不总是意味着发生临床症状。如果一个无症状的过敏原敏感患者有鼻中隔偏曲(DSN),且可能会引起鼻腔阻塞